251. Brain insulin lowers circulating BCAA levels by inducing hepatic BCAA catabolism.
- Author
-
Shin AC, Fasshauer M, Filatova N, Grundell LA, Zielinski E, Zhou JY, Scherer T, Lindtner C, White PJ, Lapworth AL, Ilkayeva O, Knippschild U, Wolf AM, Scheja L, Grove KL, Smith RD, Qian WJ, Lynch CJ, Newgard CB, and Buettner C
- Subjects
- 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) metabolism, Amino Acids, Branched-Chain metabolism, Animals, Caenorhabditis elegans, Diabetes Mellitus, Type 2 metabolism, Diet, High-Fat adverse effects, Hyperglycemia blood, Hyperglycemia metabolism, Male, Mice, Obesity metabolism, Rats, Rats, Sprague-Dawley, Signal Transduction, Amino Acids, Branched-Chain blood, Brain metabolism, Insulin metabolism, Liver metabolism
- Abstract
Circulating branched-chain amino acid (BCAA) levels are elevated in obesity/diabetes and are a sensitive predictor for type 2 diabetes. Here we show in rats that insulin dose-dependently lowers plasma BCAA levels through induction of hepatic protein expression and activity of branched-chain α-keto acid dehydrogenase (BCKDH), the rate-limiting enzyme in the BCAA degradation pathway. Selective induction of hypothalamic insulin signaling in rats and genetic modulation of brain insulin receptors in mice demonstrate that brain insulin signaling is a major regulator of BCAA metabolism by inducing hepatic BCKDH. Short-term overfeeding impairs the ability of brain insulin to lower BCAAs in rats. High-fat feeding in nonhuman primates and obesity and/or diabetes in humans is associated with reduced BCKDH protein in liver. These findings support the concept that decreased hepatic BCKDH is a major cause of increased plasma BCAAs and that hypothalamic insulin resistance may account for impaired BCAA metabolism in obesity and diabetes., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF